Gufic Biosciences Limited Share Price & Analysis
Price Chart
Fundamentals
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,783 | ₹4.3L Cr | 34.4 | 5.12 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,616 | ₹1.7L Cr | 66.1 | 10.48 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,416 | ₹1.5L Cr | 66.4 | 17.81 | 27.6 | 15.4 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,315 | ₹1.2L Cr | 59.5 | 12.62 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,402 | ₹1.1L Cr | 27.3 | 3.29 | 12.4 | 16.6 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,091 | ₹1.1L Cr | 20 | 4.05 | 21.2 | 21.2 | 0.38 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,283 | ₹1.1L Cr | 25.4 | 2.83 | 11.8 | 13.6 | 0.16 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
GUFICBIO · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.51% | 72.51% | 72.51% | 72.51% | 72.51% | 72.51% |
| FII | 0.47% | 0.12% | 0.23% | 0.23% | 0.30% | 0.31% |
| DII | 1.72% | 2.20% | 2.38% | 2.51% | 2.99% | 3.39% |
| Public | 25.29% | 25.17% | 24.89% | 24.75% | 24.20% | 23.79% |
Corporate Events
To consider and approve, inter alia, the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and financial year ended March 31, 2026, dividend and other business matters
Dividend - Re 0.10 Per Share
Annual General Meetingdividend - Re 0.10 Per Share
Annual General Meeting/Dividend - Re 0.10 Per Share
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹231 Cr ▼2.5% | ₹237 Cr ▲5.8% | ₹224 Cr ▲9.3% | ₹205 Cr ▼1.4% | ₹208 Cr ▲2.0% | ₹204 Cr ▲0.5% | ₹203 Cr ▲4.1% | ₹195 Cr |
| Op. Profit | ₹33 Cr ▼13.2% | ₹38 Cr ▲15.2% | ₹33 Cr ▲26.9% | ₹26 Cr ▼23.5% | ₹34 Cr ▼12.8% | ₹39 Cr ▲8.3% | ₹36 Cr ▲5.9% | ₹34 Cr |
| OPM | 14.0% ▼12.5% | 16.0% ▲6.7% | 15.0% ▲15.4% | 13.0% ▼18.8% | 16.0% ▼15.8% | 19.0% ▲5.6% | 18.0% ▲0.0% | 18.0% |
| Net Profit | ₹12 Cr ▼29.4% | ₹17 Cr ▲30.8% | ₹13 Cr ▲62.5% | ₹8 Cr ▼57.9% | ₹19 Cr ▼13.6% | ₹22 Cr ▲4.8% | ₹21 Cr ▲5.0% | ₹20 Cr |
| EPS (₹) | 1.24 ▼26.2% | 1.68 ▲29.2% | 1.3 ▲68.8% | 0.77 ▼60.1% | 1.93 ▼11.1% | 2.17 ▲4.3% | 2.08 ▲4.0% | 2 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| Revenue | ₹944 Cr ▲15.1% | ₹820 Cr ▲1.6% | ₹807 Cr |
| Expenses | ₹793 Cr ▲15.9% | ₹684 Cr ▲4.1% | ₹657 Cr |
| Op. Profit | ₹151 Cr ▲11.0% | ₹136 Cr ▼9.3% | ₹150 Cr |
| OPM | 16.0% ▼5.9% | 17.0% ▼10.5% | 19.0% |
| Other Income | ₹3 Cr ▼25.0% | ₹4 Cr | ₹0 Cr |
| Interest | ₹37 Cr ▲48.0% | ₹25 Cr ▲47.1% | ₹17 Cr |
| Depreciation | ₹31 Cr ▲47.6% | ₹21 Cr ▲23.5% | ₹17 Cr |
| PBT | ₹87 Cr ▼7.4% | ₹94 Cr ▼19.0% | ₹116 Cr |
| Tax % | 26.0% ▲0.0% | 26.0% ▲0.0% | 26.0% |
| Net Profit | ₹64 Cr ▼8.6% | ₹70 Cr ▼18.6% | ₹86 Cr |
| EPS (₹) | 6.4 ▼7.9% | 6.95 ▼19.1% | 8.59 |
| Div Payout | 0.0% ▼100.0% | 1.0% ▲0.0% | 1.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 |
|---|---|---|---|---|
| Liabilities | ||||
| Equity Capital | ₹10 Cr ▲0.0% | ₹10 Cr ▲0.0% | ₹10 Cr ▲0.0% | ₹10 Cr |
| Reserves | ₹655 Cr ▲5.5% | ₹621 Cr ▲5.1% | ₹591 Cr ▲13.0% | ₹523 Cr |
| Borrowings | ₹405 Cr ▲9.8% | ₹369 Cr ▲9.8% | ₹336 Cr ▲0.9% | ₹333 Cr |
| Other Liabilities | ₹273 Cr ▲0.7% | ₹271 Cr ▲16.8% | ₹232 Cr ▲2.2% | ₹227 Cr |
| Total Liabilities | ₹1.3K Cr ▲5.6% | ₹1.3K Cr ▲8.7% | ₹1.2K Cr ▲7.0% | ₹1.1K Cr |
| Assets | ||||
| Fixed Assets | ₹491 Cr ▼0.8% | ₹495 Cr ▼2.2% | ₹506 Cr ▲218.2% | ₹159 Cr |
| CWIP | ₹22 Cr ▼8.3% | ₹24 Cr ▲9.1% | ₹22 Cr ▼92.8% | ₹307 Cr |
| Investments | ₹2 Cr ▲0.0% | ₹2 Cr ▲0.0% | ₹2 Cr ▲0.0% | ₹2 Cr |
| Other Assets | ₹827 Cr ▲10.3% | ₹750 Cr ▲17.2% | ₹640 Cr ▲2.4% | ₹625 Cr |
| Total Assets | ₹1.3K Cr ▲5.6% | ₹1.3K Cr ▲8.7% | ₹1.2K Cr ▲7.0% | ₹1.1K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| Operating CF | — | ₹123 Cr ▲1857.1% | ₹-7 Cr |
| Investing CF | — | ₹-71 Cr ▲30.4% | ₹-102 Cr |
| Financing CF | — | ₹-37 Cr ▼145.1% | ₹82 Cr |
| Net Cash Flow | — | ₹15 Cr ▲155.6% | ₹-27 Cr |
| Free Cash Flow | — | ₹52 Cr ▲144.8% | ₹-116 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| Debtor Days | 115d ▼17.9% | 140d ▼6.0% | 149d |
| Inventory Days | 281d ▲33.2% | 211d ▲12.2% | 188d |
| Days Payable | 172d ▲11.0% | 155d ▼0.6% | 156d |
| Cash Conv. Cycle | 224d ▲13.7% | 197d ▲8.8% | 181d |
| Working Capital Days | 80d ▼14.0% | 93d ▼4.1% | 97d |
| ROCE | 12.0% ▼7.7% | 13.0% | — |
Source: Screener.in · Lower days = better efficiency
About Gufic Biosciences Limited
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
Healthcare · Pharmaceuticals & Biotechnology